1 / 23

Nancy Padian Senior technical consultant OGAC/PEPFAR UC Berkeley

Use of Antivirals in Prevention: Current Challenges and Controversies : Treatment for Prevention IAS 2011. Nancy Padian Senior technical consultant OGAC/PEPFAR UC Berkeley. Outline. Review of the evidence Implementation Science Challenges Burden on health systems

keziah
Télécharger la présentation

Nancy Padian Senior technical consultant OGAC/PEPFAR UC Berkeley

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Use of Antivirals in Prevention: Current Challenges and Controversies:Treatment for PreventionIAS 2011 Nancy Padian Senior technical consultant OGAC/PEPFAR UC Berkeley

  2. Outline • Review of the evidence • Implementation Science Challenges • Burden on health systems • Testing and linkages to care • Eligibility • Adherence • Prioritizing distribution

  3. Evidence for treatment for prevention

  4. Ecological Studies and ART Population Level Benefit San Francisco (PloS One, 2010) British Columbia (Lancet, 2010) Ambiguous Benefit? Amsterdam France Australia

  5. (Cohen et al, Current Opinion HIV 2011)

  6. Modeling Population-Level ART Effects Cohen and Gay, CID 2010

  7. HPTN 052 1763 discordant heterosexual couples (9 countries, 13 sites) Randomization Deferred ART CD4 <250 Immediate ART 350-550cells/uL AZT+3TC+EFV Endpoints: i) HIV transmission to partners ii) OIs and clinical events iii) ART toxicity

  8. HPTN 052 Prevention Results • 39 total infections, 35 in the delayed arm (p<.0001) • 28 linked infections (by 3 independent methods) • 27 delayed arm • 1 immediate arm • 17 of 27 infections in delayed arm occurred when the index participants’ CD4 was >350 • 7 unlinked infections • 4 delayed arm (all now proven unlinked) • 3 immediate arm (all now proven unlinked) • 4 infections still being analyzed (all in the delayed arm) • The details of 1/27 transmissions are being evaluated p<0.001

  9. Effect of ART at Population Level • Depends on: • durable and reliable HIV suppression • preventing transmitted resistance • dealing with acute HIV infection • numerous implementation issues

  10. Implementation Science Challenges

  11. Added Burden to Health System • Human Resources • Task shifting • Increased training • Structural Resources • Centralized and Decentralized care • Increased Commodities • (e.g. test kits, drugs)

  12. HIV testing and linkages to care • Consider supply side interventions • PBF/P4P • CCT • Develop service delivery models that: • Optimize testing uptake and increase demand • Optimize linkages to care and treatment • Protect patient rights and confidentiality • Examples • Demand-side incentives • Home-based, door-to-door testing • Non-medical venues (hair salons, markets)

  13. Knowledge of HIV Status among PLWH – Kenya 16% knew they were positive 56% never tested for HIV 28% reported last HIV-test negative 84% of HIV-infected adults did not know their status. KAIS, 2008

  14. Gardner et al, CID. 2010: “ We estimate that only 19% of HIV-infected individuals in the United States have an undetectable HIV load.”

  15. Barriers to Introducing & Scaling up Core Interventions for IDUs • NSP • Police harassment • Administrative and pretrial detention without due process • Type of syringes distributed not always acceptable • High threshold policies and programmatic requirements constrain program and coverage • Test • Stigma and discrimination • Testing in government-run facilities • Lack of confidentiality of test results • No or limited/inaccessible services available • Operational policies limit accessibility of testing (e.g. Only phlebotomists can administer test, limited use of rapid testing technologies, delay in receipt of positive results)

  16. Barriers to Introducing & Scaling Up Core Interventions for IDUs • Treat • ART • Eligibility criteria excludes active IDUs from ART • MAT often necessary before approval for ART initiation • Stock outs of ART • MAT not widely available • MAT • Register with authorities before eligible for services • Police harassment • Information shared between health and law enforcement • Lose rights to gainful employment, child custody • High threshold policies and programmatic requirements constrain program and coverage • Stock outs

  17. Eligibility • Right people, right drug concentration, right agent, right time • Requires high uptake of frequent testing • How to identify most contagious people early • Early, acute infection • Challenges linking asymptomatic people to care • Need for acute infection incidence assay

  18. Powers et al, Lancet 2011. Overall 38.4% of HIV transmissions in Lilongwe attributed to sexual contact with individuals with early infection

  19. Adherence • Innovative strategies for real time monitoring • Less adherent-dependent doses • Innovative delivery systems; long-acting, slow release • Rings • Implants • Patches • Better tolerated products

  20. A cornerstone for combination prevention • Behavior change • Adherence • Risk compensation • condoms • number of partners • Links to: circumcision, PMTCT, PrEP, care, structural programs (especially for young women)

  21. How to Prioritize Distribution • Pregnant women • Discordant couples • Stigmatized and marginalized high risk groups • (e.g. FSW, IDU, HIV+) • Children Challenge is how to ensure equity when treatment is not yet available to all who need it

  22. Many Thanks!! Mike Cohen WafaaEl-Sadr Rich Needles

More Related